HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- 1- hydroxymethyl- 2,3- dihydroxypropyl- 2,2,5,5- tetramethylpyrrolidin- 1- oxyl- 3- carboxamide

structure given in first source

Also Known As:

NAT-N

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Heterocyclic Oxides
  - Cyclic N-Oxides: 3
    - N-1-hydroxymethyl-2,3-dihydroxypropyl-2,2,5,5-tetramethylpyrrolidin-1-oxyl-3-carboxamide: 6

Experts

1.	Bi, Zhao: 1 article (01/2021)
2.	Chang, Jin: 1 article (01/2021)
3.	Chen, Peng: 1 article (01/2021)
4.	Chi, Yajing: 1 article (01/2021)
5.	Li, Huihui: 1 article (01/2021)
6.	Man, Xiaochu: 1 article (01/2021)
7.	Qiu, Peng-Fei: 1 article (01/2021)
8.	Shang, Mao: 1 article (01/2021)
9.	Song, Xian-Rang: 1 article (01/2021)
10.	Song, Xing-Guo: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 07/04/2017 - "To investigate the diagnostic potentials of microRNA-451(miR-451) in papillary thyroid carcinoma (PTC) diagnosis and lymph node (LN) metastasis, formalin-fixed, paraffin-embedded (FFPE) tissue specimens corresponding to PTC tumors (n= 60) and their normal counterparts (Normal tissues Adjacent to Tumor, NAT, n= 60), along with sera from PTC patients with malignant tumors (n= 70) and benign lesions (n= 70) were analyzed for the expression of miR-451 by real-time PCR. " 01/01/2021 - "Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2021 - "HER2-positive breast cancer cases receiving neoadjuvant treatment (NAT; n = 155) were retrospectively collected from July 2013 to November 2018. " 01/01/2021 - "Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. "
3.	Drug-Related Side Effects and Adverse Reactions 01/01/2004 - "Abbreviations used will be as follows: ACEI, ACE inhibitor; ADR, adverse drug reaction; ANA, antinuclear antigen; ARB, angiotensin II receptor blocker; BAB, beta-adrenergic blocker; CCB, calcium-channel blocker; CDR, cutaneous drug reaction; CVD, cardiovascular drug; CYP, cytochrome P450 enzyme; EM, erythema multiforme; FDE, fixed drug eruption; I, inhibitor of CYP isoform activity; HMG-CoA, hydroxymethyl-glutaryl coenzyme A; NAT, N-acetyltransferase; ODR, oral drug reaction; RDM, reactive drug metabolite; S, substrate for CYP isoform; SJS, Stevens-Johnson syndrome; SLE, systemic lupus erythematosus; and TEN, toxic epidermal necrolysis."
4.	Stomach Neoplasms (Stomach Cancer) 01/01/2018 - "The expression levels of DGCR9 in each patient between formalin-fixed, paraffin-embedded (FFPE) gastric cancer tissues and adjacent noncancer tissues (NAT) (n=102) were measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). "
5.	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/01/2004 - "Abbreviations used will be as follows: ACEI, ACE inhibitor; ADR, adverse drug reaction; ANA, antinuclear antigen; ARB, angiotensin II receptor blocker; BAB, beta-adrenergic blocker; CCB, calcium-channel blocker; CDR, cutaneous drug reaction; CVD, cardiovascular drug; CYP, cytochrome P450 enzyme; EM, erythema multiforme; FDE, fixed drug eruption; I, inhibitor of CYP isoform activity; HMG-CoA, hydroxymethyl-glutaryl coenzyme A; NAT, N-acetyltransferase; ODR, oral drug reaction; RDM, reactive drug metabolite; S, substrate for CYP isoform; SJS, Stevens-Johnson syndrome; SLE, systemic lupus erythematosus; and TEN, toxic epidermal necrolysis."

Related Drugs and Biologics

1.	Paraffin
2.	Formaldehyde (Formol)
3.	Long Noncoding RNA
4.	Angiotensin Receptor Antagonists
5.	Protein Isoforms (Isoforms)
6.	Biomarkers (Surrogate Marker)
7.	RNA (Ribonucleic Acid)
8.	Enzymes
9.	Cytochrome P-450 Enzyme System (Cytochrome P450)
10.	Cardiovascular Agents

Related Therapies and Procedures

1.	Neoadjuvant Therapy